HAIROID™️ presented the above shown poster “METHODS FOR DERIVING HAIR FOLLICLE CONTAINING SHEETS IN VITRO” at 2019 WCHR’ meeting in Barcelona/SPAIN, which was enthusiastically commented by various participants.


03. MAY 2019


*Fig 2 | Cumulative incidence of type 2 diabetes in Clinical Practice Research Datalink cohort over study period: main cohort (adjusted), and adjusted for propensity score

HAIROID™️ is introducing a study named : „Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors [Dutasteride/Finasteride]: population based cohort study“.  By Li Wei, Edward Chia-Cheng Lai, Yea-Huei Kao-Yang,Brian R Walker, Thomas M MacDonald, Ruth Andrew - indicating a clear correlation between Dutasteride/Finasteride and Diabetes Mellitus Type 2!


11. May 2019


HAIROID™️ introduces it's latest patent development concerning hypoimmunogenic Hairfollicles, hypimmunogenic Dermal Papillae Cells and hypoimmunogenic Melanocytes. This technology can be used for already engineered and cryopreserved cell- lines. With the development of  hypimmunogenic Dermal Papillae Cells and hypoimmunogenic Melanocytes we believe we can contribute massive to the advancement of STEMCELLTHERAPIES in regards to hair rejuvenation and hair repigmentation.

The newest [HAIROID™️] invention provides a method for the generation of hypoimmunogenic hair follicles that can be used as an off-shelf universal donor source for allogenic transplantation, allogeneic rejuvenation and allogeneic repigmentation of hair. This is achieved by removing key MHCI/II genes together with enhanced expression of genes which increase the immunotolerance in allogenic iPSC, DPC and NHM. Following these genetic modifications, allogenic iPSC, DPC  and NHM are used to develop hypoimmunogenic hair follicles and related STEMCELLTHERAPIES as outlined.


13. August  2019



HAIROID™️ provides CRO/CMO services and assistance in two upcoming clinical trails in relation with it’s proprietary IP. 

07. March 2020

Fig. Structure of Angiotensin converting enzyme II (ACE2) expressed on the surface of cells in human airways epithelia.


HAIROID™️ provides Insilico CRO/CMO services and tissue engineering competence  in the fight against COVID-19. We participate in a consortium with 3 Universities and one research institute in order to screen compounds with engineered  3 d mucosa stemcell tissues and test various antiviral compounds, with efficiency in SARS-Cov-2 (“Coronavirus”).

Furthermore we provide antiviral bio polymer films to healthcare agencies and protection gear manufacturers.

All previous laboratory activities are directed towards these targets. 

Our new AI / Insilico modeling team starts ASAP  the development of AI/Insilico modeled  airway epithelial tissues in order to accelerate the identification of effective compounds or cell therapies against COVID19.

We expect to continue our regular activities  in early Q3 2020.

Please all stay safe [and at home]. #allhandsondeck 

26. March 2020